Deutsche Bank AG Makes New Investment in AxoGen, Inc. $AXGN

Deutsche Bank AG bought a new stake in AxoGen, Inc. (NASDAQ:AXGN) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 651,784 shares of the medical equipment provider’s stock, valued at approximately $30,106,000. Deutsche Bank AG owned about 1.21% of AxoGen as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Rice Hall James & Associates LLC purchased a new stake in AxoGen during the 2nd quarter valued at about $3,414,000. TimesSquare Capital Management LLC acquired a new position in shares of AxoGen during the 2nd quarter worth approximately $31,863,000. IMC Chicago LLC purchased a new stake in shares of AxoGen in the second quarter valued at approximately $386,000. Bank of New York Mellon Corp purchased a new stake in shares of AxoGen in the second quarter valued at approximately $7,042,000. Finally, State of Wyoming acquired a new stake in shares of AxoGen in the second quarter valued at approximately $281,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at AxoGen

In other news, Director Kathy Johnson Weiler sold 14,150 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the sale, the executive vice president owned 50,135 shares in the company, valued at $2,373,390.90. The trade was a 57.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 95,003 shares of company stock valued at $4,482,997 in the last quarter. Corporate insiders own 2.44% of the company’s stock.

AxoGen Price Performance

AxoGen stock opened at $50.40 on Friday. The firm has a market cap of $2.71 billion, a PE ratio of -74.12 and a beta of 1.11. AxoGen, Inc. has a 52-week low of $13.64 and a 52-week high of $51.06. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. The company’s 50 day moving average is $44.11 and its two-hundred day moving average is $38.96.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.12. The business had revenue of $69.73 million for the quarter, compared to analysts’ expectations of $67.10 million. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%. On average, research analysts expect that AxoGen, Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on AXGN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of AxoGen in a research note on Friday, May 29th. Citizens Jmp lifted their price target on AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Thursday, July 30th. Truist Financial set a $55.00 price target on shares of AxoGen in a research report on Thursday, July 30th. Citigroup reissued a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Finally, Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a research report on Friday, May 29th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.00.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.